Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,567 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 38,198 · Balance 162,567 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 202,759 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 202,759 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 156,589 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 46,170 · Balance 156,589 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 194,786 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 194,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418308 · ownership.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 46,170 | $38.61 | $1,782,623.70 |
DisclosureSEC source: 0001193125-26-418308 · ownership.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,589 F4 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 40,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418308 · ownership.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,759 F3 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 38,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418308 · ownership.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,567 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 470 | $36.69 | $17,244.30 |
DisclosureSEC source: 0001628280-26-063079 · wk-form4_1790111515.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,823 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 356 | $35.38 | $12,595.28 |
DisclosureSEC source: 0001628280-26-061389 · wk-form4_1789073439.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,293 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| July 07, 2026 Filed Jul 13, 2026 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 293 | $27.79 | $8,142.47 |
DisclosureSEC source: 0001628280-26-048052 · wk-form4_1783976597.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,649 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 470 | $26.04 | $12,238.80 |
DisclosureSEC source: 0001628280-26-044699 · wk-form4_1782161430.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,942 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 21:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 356 | $26.10 | $9,291.60 |
DisclosureSEC source: 0001628280-26-042285 · wk-form4_1781125282.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,412 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 293 | $19.27 | $5,646.11 |
DisclosureSEC source: 0001628280-26-024766 · wk-form4_1775856558.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,768 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 1,879 | $19.12 | $35,926.48 |
DisclosureSEC source: 0001628280-26-020580 · wk-form4_1774300140.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,061 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 353 | $20.74 | $7,321.22 |
DisclosureSEC source: 0001628280-26-015336 · wk-form4_1772748602.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,940 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 8,846 | $22.65 | $200,361.90 |
DisclosureSEC source: 0001628280-26-012481 · wk-form4_1772146575.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,293 F3 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 22,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012481 · wk-form4_1772146575.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,139 F2 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012481 · wk-form4_1772146575.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,660 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 344 | $25.59 | $8,802.96 |
DisclosureSEC source: 0001628280-26-001382 · wk-form4_1767909830.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,564 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 09, 2025 Filed Dec 17, 2025 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 358 | $25.13 | $8,996.54 |
DisclosureSEC source: 0001628280-25-057720 · wk-form4_1766010349.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,908 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 351 | $26.74 | $9,385.74 |
DisclosureSEC source: 0001628280-25-054283 · wk-form4_1764369345.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,266 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 21:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 289 | $27.36 | $7,907.04 |
DisclosureSEC source: 0001628280-25-045018 · wk-form4_1760477442.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,617 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 358 | $26.83 | $9,605.14 |
DisclosureSEC source: 0001633186-25-000005 · wk-form4_1757970125.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,906 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:06 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 354 | $25.44 | $9,005.76 |
DisclosureSEC source: 0001628280-25-041299 · wk-form4_1756415213.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,264 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $25.53 | $255,300.00 |
DisclosureSEC source: 0001633186-25-000003 · wk-form4_1756328410.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,618 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 304 | $22.27 | $6,770.08 |
DisclosureSEC source: 0001628280-25-034681 · wk-form4_1752098033.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,618 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 362 | $23.70 | $8,579.40 |
DisclosureSEC source: 0001628280-25-031103 · wk-form4_1749763471.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,922 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:06 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 348 | $22.46 | $7,816.08 |
DisclosureSEC source: 0001628280-25-028704 · wk-form4_1748642758.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,284 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 324 | $20.11 | $6,515.64 |
DisclosureSEC source: 0001628280-25-017586 · wk-form4_1744408146.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,632 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 8,902 | $22.66 | $201,719.32 |
DisclosureSEC source: 0001628280-25-016636 · wk-form4_1743716906.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,956 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014183 · wk-form4_1742512080.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,858 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 19,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014183 · wk-form4_1742512080.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,060 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,577 | $25.00 | $39,425.00 |
DisclosureSEC source: 0001628280-25-012681 · wk-form4_1741901189.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,961 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 424 | $25.46 | $10,795.04 |
DisclosureSEC source: 0001628280-25-010562 · wk-form4_1741212781.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,538 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:46 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 102 | $26.54 | $2,707.08 |
DisclosureSEC source: 0001628280-25-005840 · wk-form4_1739573194.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,962 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 00:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 343 | $27.02 | $9,267.86 |
DisclosureSEC source: 0001628280-25-000985 · wk-form4_1736381449.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,064 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 22:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 349 | $27.20 | $9,492.80 |
DisclosureSEC source: 0001628280-24-049478 · wk-form4_1732919386.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,407 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 23:38 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 91 | $26.34 | $2,396.94 |
DisclosureSEC source: 0001628280-24-047995 · wk-form4_1731627486.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,756 F1 · shares: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 311 | $23.15 | $7,199.65 |
DisclosureSEC source: 0001628280-24-044814 · wk-form4_1730502110.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,847 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 367 | $25.12 | $9,219.04 |
DisclosureSEC source: 0001628280-24-040833 · wk-form4_1726695916.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,158 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 21, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 82 | $25.61 | $2,100.02 |
DisclosureSEC source: 0001628280-24-040833 · wk-form4_1726695916.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,525 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 11, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 287 | $20.54 | $5,894.98 |
DisclosureSEC source: 0001628280-24-040833 · wk-form4_1726695916.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,607 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $20.18 | $201,800.00 |
DisclosureSEC source: 0001628280-24-028838 · wk-form4_1718744412.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,894 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-15-2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.24, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 345 | $21.78 | $7,514.10 |
DisclosureSEC source: 0001628280-24-026080 · wk-form4_1717189493.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,894 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 17, 2024 Filed May 21, 2024 12:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 73 | $22.18 | $1,619.14 |
DisclosureSEC source: 0001628280-24-024449 · wk-form4_1716293618.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,239 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:34 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $22.67 | $226,700.00 |
DisclosureSEC source: 0001628280-24-024094 · wk-form4_1715978057.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,312 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-15-2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.52 to $22.81, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 23:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 332 | $15.31 | $5,082.92 |
DisclosureSEC source: 0001628280-24-017496 · wk-form4_1713914052.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,312 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 15, 2024 Filed Apr 18, 2024 12:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.67 | $156,700.00 |
DisclosureSEC source: 0001628280-24-016673 · wk-form4_1713442689.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,644 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-15-2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 515 | $17.99 | $9,264.85 |
DisclosureSEC source: 0001628280-24-013829 · wk-form4_1711748369.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,644 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 01:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,107 | $16.60 | $117,976.20 |
DisclosureSEC source: 0001628280-24-010750 · wk-form4_1710294273.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,159 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 401 | $17.42 | $6,985.42 |
DisclosureSEC source: 0001628280-24-010750 · wk-form4_1710294273.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,266 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 17,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010750 · wk-form4_1710294273.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,667 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010750 · wk-form4_1710294273.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,144 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.